CD8A and central nervous system cancer: Among them, most of the HLA, checkpoints, chemokines, costimulatory molecules, IFNG, CD8, and CD274 were highly expressed in the high-risk group, which showed that the high-risk group may get more chances from the anti-glioma immunotherapy.